ProCE Banner Activity

DESTINY-Breast03: Trastuzumab Deruxtecan vs Trastuzumab Emtansine in Previously Treated HER2+ Metastatic Breast Cancer

Slideset Download
Conference Coverage
In a head-to-head trial in patients with previously treated HER2-positive metastatic breast cancer, trastuzumab deruxtecan reduced risk of disease progression or death by 72% compared with trastuzumab emtansine, a current standard of care.

Released: September 23, 2021

Expiration: September 22, 2022

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc